Lee LK, Flores NM, Micheletti MC, Leibert R, Weiss, H, Tang B. Comparing treatment satisfaction, adherence, and menstrual symptoms between women using extended-cycle and monthly-cycle birth control pills. Poster presented at the European Board and College of Obstetrics and Gynaecology Meeting (EBCOG 2016). May 19–21, 2016.
The real-world experience of women receiving extended-cycle combined oral contraception (COC) versus monthly-cycle COC has not been reported.
Data were from the United States 2013 National Health and Wellness Survey. Eligible women (18–50 years old, premenopausal, without hysterectomy) currently using extended-cycle COC (3 months between periods) were compared with women using monthly-cycle COC. Treatment satisfaction (1 “extremely dissatisfied” to 7 “extremely satisfied”), adherence (8-item Morisky Medication Adherence Scale©), menstrual cycle-related symptoms, health-related quality of life (HRQOL) and health state utilities (Medical Outcomes Short Form Survey-36v2®), depression (9-item Patient Health Questionnaire), sleep difficulties, Work Productivity and Activity Impairment-General Health, and healthcare resource use were assessed using one-way analyses of variance, chi-square tests, and generalized linear models (adjusted for covariates).
Participants included 260 (6.7%) women using extended-cycle and 3616 (93.3%) using monthly-cycle COC. Women using extended-cycle COC reported significantly higher treatment satisfaction (P = 0.001) and adherence (P = 0.04) and reduced heavy menstrual bleeding (P = 0.029). A non-significant tendency toward reduced menstrual pain (39.5% versus 47.3%) and menstrual cycle-related symptoms (40.0% versus 48.7%) was found in women using extended-cycle versus monthly-cycle COC. Significantly more women using extended-cycle COC reported health-related diagnoses, indicating preferential prescription for extended-cycle COC among women reporting more health problems. Consistent with this poorer health, more women using extended-cycle COC reported fatigue, headache, and activity impairment (P values < 0.05). There were no other significant differences between groups.
This real-world observational study supports extended-cycle COC as a valuable treatment option with high satisfaction, high adherence, and reduced heavy menstrual bleeding.
Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Invest. 2010;30:749–63. CrossRef
Nelson AL. Communicating with patients about extended-cycle and continuous use of oral contraceptives. J Womens Health (Larchmont). 2007;16:463–70. CrossRef
Nappi RE, Fiala C, Chabbert-Buffet N, Hausler G, Jamin C, Lete I, Lukasiewic M, Pintiaux A, Lobo P. Women's preferences for menstrual bleeding frequency: results of the inconvenience due to Women's monthly bleeding (ISY) survey. Eur J Contracept Reprod Health Care. 2016;21:242–50.
Edelman A, Micks E, Gallo MF, Jensen JT. Grimes DA. Continuous or extended cycle vs cyclic use of combined hormonal contraceptives for contraception Cochrane Database Syst Rev. 2014;7:CD004695.
Mendoza N, Lobo P, Lertxundi R, Correa M, Gonzalez E, Salamanca A, Sanchez-Borrego R. Extended regimens of combined hormonal contraception to reduce symptoms related to withdrawal bleeding and the hormone-free interval: a systematic review of randomised and observational studies. Eur J Contracept Reprod Health Care. 2014:19:321–39.
McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC, Langenberg P, Roghmann MC, Harris AD. Utility of the chronic disease score and Charlson Comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005;161:483–93. CrossRefPubMed
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10:348–54. CrossRef
Mariush MEEd. User's manual for the SF-36v2® health survey. 3rd ed. Quality Metric Incorporated: Lincoln, RI; 2011.
Huppertz-Hauss G, Aas E, Lie Hoivik M, Langholz E, Odes S, Smastuen M, Stockbrugger R, Hoff G, Moum B, Bernklev T. Comparison of the multiattribute utility instruments EQ-5D and SF-6D in a Europe-wide population-based cohort of patients with inflammatory bowel disease 10 years after diagnosis. Gastroenterol Res Pract. 2016;2016:5023973. CrossRefPubMedPubMedCentral
Guilbert E, Boroditsky R, Black A, Kives S, Leboeuf M, Mirosh M, Senikas V, Wagner MS, Weir E, York-Lowry J, Reid R, Trussell J. Canadian consensus guideline on continuous and extended hormonal contraception, 2007. J Obstet Gynaecol Can. 2007;29:S1–S32. CrossRef
Wasiak R, Filonenko A, Vanness DJ, Law A, Jeddi M, Wittrup-Jensen KU, Stull DE, Siak S, Jensen JT. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Women's Health. 2013;22:378–84. CrossRef
Barnard K, Frayne SM, Skinner KM, Sullivan LM. Health status among women with menstrual symptoms. J Women's Health. 2003;12:911–9. CrossRef
- Real-world experience of women using extended-cycle vs monthly-cycle combined oral contraception in the United States: the National Health and Wellness Survey
Rossella E. Nappi
Lulu K. Lee
Natalia M. Flores
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
e.Med Kampagnen-Visual, Mail Icon II